Multiple endocrine neoplasia type 1 (MEN1) syndrome is characterized by the occurrence of tumors of parathyroids, neuroendocrine cells of the gastro-enteropancreatic tract and anterior pituitary. MEN1 gene encodes menin-oncosuppressor protein. Loss of heterozygosity at 11q13 is typical of MEN1 tumors. We have analyzed the MEN1 mRNA and menin expression in fibroblasts from normal skin biopsies and from MEN1 patients (two with a frameshift 738del4 (exon 3) mutation, introducing a premature stop codon, and an individual with an R460X (exon 10) nonsense mutation). The expression of full-length menin protein did not differ between MEN1 and normal fibroblasts. Wild-type alleles mRNAs were expressed in MEN1 patients, whereas mutant alleles were partially degraded by nonsense-mediated mRNA decay pathway, suggesting a mechanism of compensation for allelic loss by the up-regulation of wild-type menin expression at a post-transcriptional level. Small-interfering RNA silencing of the wildtype mRNA allele abolished menin compensation, whereas the ribozyme silencing of the MEN1-mutated mRNA allele resulted in strongly enhanced wild-type menin expression. Gel-retardation analysis showed that in vitro-specific RNA-protein complexes bound to MEN1 mRNA. These findings contribute to the understanding of tumorigenesis in MEN1, offering the basis for the development of RNA-based therapies in MEN1 gene mutation carriers.
Introduction
The hallmark of multiple endocrine neoplasia type 1 (MEN1) is the development of tumors in the parathyroids, in the enteropancreatic endocrine tissue and in the anterior pituitary. Other associations found in MEN1 patients include foregut carcinoids, facial angiofibromas, lipomas, collagenomas, meningiomas and smooth muscle cell tumors. [1] [2] [3] [4] [5] MEN1 patients typically inherit germline loss of function mutations in the MEN1 gene, and tumors arise when the somatic loss of the retained wild-type allele occurs. Thus, the MEN1 gene follows the classic 'two-hit' tumor-suppressor model, first proposed by Knudson 6 for retinoblastoma. The ubiquitously expressed product of MEN1, menin, is a 67-kDa protein found predominantly in the nucleus. 7 Studies in Men1 knockout mice support a tumor-suppressor function for menin. [8] [9] [10] [11] [12] [13] [14] The development of tumors in an endocrine-specific pattern is puzzling as menin appears to be expressed in all tissues. Menin has been reported to interact with a multitude of proteins including JunD, SMAD family members, Pem, NFkB, FANCD2, RPA2, NMMHC II-A, GFAP, vimentin and Hsp70. 15 The diverse functions of the menin partners suggest functions for menin in transcriptional regulation, DNA processing, repair and recombination, cytoskeletal organization and protein degradation, although to date none of the interacting partners have been directly proved important in MEN1 pathophysiology. [15] [16] [17] [18] [19] [20] [21] Conversely, little is known about how MEN1 gene itself is regulated. Studies on cell cycle-dependent expression of menin have led to contradictory results. [22] [23] [24] RNA in situ hybridization of sporadic parathyroid tumors showed no difference in menin expression between normal and tumor tissues. 2 Moreover, in cell lines from MEN1 patients, the expression of wild-type protein did not differ from healthy controls. 24 These results suggest that cellular attempts to compensate for MEN1 allelic loss by up-regulating the expression of menin from the retained allele. Several alternatively spliced MEN1 transcripts have been identified both in human beings and in mice, [25] [26] [27] being displayed in multiple tissues as two major bands. All splice variants identified so far differ in their first, untranslated exon and encode the same protein. 25 RNA in situ hybridization on mouse tissues has revealed a differential spatial/temporal expression pattern of the splice variants. 25 In human beings, a larger transcript (4.2 kb) may be expressed in a more restricted manner than the ubiquitously expressed 2.9-kb transcript. 28 In response to down-regulation of MEN1 expression by RNA interference, the regulatory region activated the promoter in a compensatory manner. 29 These data prompted the authors to speculate that the expression of the MEN1 gene is regulated through a feedback mechanism from its product menin. 29 In this study, we focused on the analysis of the in vitro expression of MEN1 mRNA and menin in primary cell cultures from both healthy fibroblasts and fibroblasts obtained from MEN1 patients using RNA silencing approaches. We showed, for the first time, an RNAbinding activity of menin that may modulate the mechanism of induction of menin-oncosuppressor expression and its function in transcriptional regulation.
Materials and methods

Subjects
Skin fibroblasts were obtained from two healthy donors (coded as C21 and A49) and from three female MEN1 patients (coded MEN1-A, MEN1-B and MEN1-C). This study was approved by the Institutional Review Board. Informed consent was obtained from all the subjects involved in the study. The clinical features of the MEN1 patients are depicted in Table 1a .
We collected parathyroid adenomas from four MEN1 patients exhibiting four different MEN1 gene mutations and 11q13 loss of heterozigosity (LOH) (Table 1b) . A normal human parathyroid tissue has been used as healthy control.
Isolation of skin fibroblasts
Human fibroblasts were obtained by skin biopsy from the medial part of the arm of the donors in accordance with a protocol approved by the Institutional Review Board for human studies. Two primary cell lines were obtained by healthy subjects (a 30-year-old woman (C21) and a 25-year-old man (A49), respectively) and were included as controls. MEN1-A, MEN1-B and MEN1-C fibroblastic cells were obtained by three MEN1 patients. The skin biopsies were cut into 0.2-0.5 mm fragments and placed under a slide in a 60-mm culture dish containing 5 ml of Ham's F12 Coon's modification medium with 100 IU ml -1 penicillin, 100 mg ml -1 streptomycin (BioWhittaker, Cambrex, Belgium) and 20% fetal bovine serum (Australian origin, BioWhittaker). The dishes were incubated at 37 1C in humidified atmosphere 5% CO 2 /95% air, with medium changed twice a week until subconfluence was reached. In the successive passages. fibroblasts were cultured in 10% fetal bovine serum medium. All the cells were used between the fifth and seventh passage.
MEN1 gene mutational analysis
Genomic DNA of the three MEN1 patients was extracted from peripheral blood leukocytes using a microvolume silica membrane-based column system according to the manufacture's instruction (NucleoSpin Blood Quick Pure, Macherey-Nagel, Easton, PA). Mutational analysis of the encoding regions (exons 2-10) and of the intron-exon junctions of the MEN1 gene was performed by direct sequencing as previously described. Treatment of cultured cell with puromycin Primary fibroblasts were routinely grown as described above, and then treated with puromycin to suppress the nonsense-mediated mRNA decay (NMD). For drug treatment, some 2 Â 10 5 cells were transferred into 10 cm Petri dishes, grown to 80% confluence and subsequently exposed to a final concentration of 200 ı`g puromycin per ml medium for 6 and 12 h.
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MEN1 mRNA silencing by small-interfering RNAs and 'hammerhead' ribozymes MEN1 mRNA has been silenced by transfecting healthy control and MEN1 fibroblasts with a specific anti-MEN1 small-interfering RNA (siRNA) or modified anti-MEN1 'hammerhead' ribozymes. RNA oligonucleotides were purchased from IBA (Gottingen, Germany). Human fibroblasts were transfected with siRNA duplexes (200 pmol) or ribozymes (250 nmol) by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Cells were harvested 48 h after initial transfection and proteins and RNAs were isolated by using 'PARIS' (Ambion, Austin, TX).
The sequences of siRNAs used were the following:
The sequences of modified 'hammerhead' ribozymes used were as follows:
Rz.738del4 5 0 -C*GGCAUUCUGAUGAGGCCGAA AGGCCGAAACUGGC*C-3 0 ; Rz.738del4M C*GGCAUUCUAAUGAGGCCGAAA GGCCGAGACUGGC*C-3 0 ; Rz.WT 5 0 -C*GGCAUUCUGAUGAGGCCGAAA GGCCGAAACUGUC*U-3 0 ; 2 0 -fluoro-2 0 -deoxypyrimidine nucleotides, 2 0 -amino-2 0 -deoxyuridine nucleotides, underlined; S, phosphorothioate linkages. Bold indicate the two mutations in the catalytic core, G5A and A14G.
Plasmid construction pT7MEN1plasmid was constructed by inserting PCRamplified human full-length MEN1 cDNA from health patient fibroblasts into pCRII (Invitrogen). Positive clones were screened by PCR and then sequenced to confirm the fidelity of the sequence.
Loss of heterozygosity analysis
Microsatellite-PCR-based analysis for LOH in the MEN1 region was performed in fibroblasts and blood DNA samples from the MEN1 patients. LOH analysis was performed using four specific microsatellite markers (D11S480, PYGM, D11S449, D11S913) flanking the 11q12-13 locus. Four independent PCR amplifications were performed separately in a final volume of 12.5 ml 
Real-time quantitative RT-PCR
Real-time quantitative RT-PCR (real-time qRT-PCR) was carried out for MEN1 and pro-Caspase 8 genes. For each analyzed subject, the experiments were replicated on two different cell samples; 10 mg of total RNA from each sample were DNAse treated with DNA-free kit (Ambion). A total of 20 mg of DNAse-treated RNA were amplified using one-step Brilliant SYBR Green QRT-PCR Master mix kit (Stratagene, La Jolla, CA) and 400 nM of forward and reverse primers. Each RNA sample was evaluated for transcript levels in triplicate (including the normalization control b-actin) and quantified with MX3000P multiplex quantitative PCR instrument (Stratagene) following a unique three-step protocol: one cycle of initial incubation at 50 1C for 30 min for reverse reaction, one cycle at 95 1C for 10 min to fully activate DNA polymerase and 40 amplification cycles (95 1C for 30 s, 1 min at the appropriate annealing temperature and 72 1C for 30 s). Sample fluorescence was detected during the annealing step. Finally, the amplified product was incubated for 1 min at 95 1C for denaturation, then ramped down to 55 1C and finally ramped up from 55 to 95 1C for the dissociation curve at a rate of 0.2 1C per second. The fluorescence data were collected continuously to obtain the dissociation curve. Fluorescence was plotted versus the Ct (threshold cycle) based on dRn (baseline-corrected, reference dye-normalized fluorescence) to obtain the standard curve and to measure the initial template quantity. Gene expression was normalized to b-actin. Fluorescence data were analyzed using MXPro Software. Primers were CASP8-forward:
Western blotting Cell lysates were prepared by the PARIS purification kit. To evaluate pro-caspase 8 expression, the blocked membrane was incubated with rabbit anti-pro-caspase-8 (sc-7890) polyclonal antibody (Santa Cruz Biotechnology) and processed as above.
In vitro transcription and cleavage kinetics For in vitro transcription, the plasmid pT7MEN1 was linearized, phenol-chloroform extracted and ethanol precipitated. In total, 2 mg of linearized plasmid DNA were transcribed by using MEGAshortscript (Ambion).
Kinetic constants for the cleavage were obtained by plotting the observed cleavage rate, k obs , against the quotient of k obs over the ribozyme concentration [E]g, according to the following equation:
The reaction rate k obs equals the negative logarithm of the remaining substrate (FracS) divided by the reaction time t. The negative slope represents the KM value and the intercept of the regression line with the ordinate gives the maximal reaction rate, kreact, under single turnover conditions. Data were fitted to the Michaelis-Menten equation by KaleidaGraph (Synergy Software, Reading, PA). The measurements were repeated three times. The catalytic efficiencies of modified hammerhead ribozymes with in vitro transcribed full-length MEN1 mRNA are shown as follows:
Microarray experiments
GEArray Q series human cancer pathway finder Gene Array (HS-006) were used for expression profiling (SuperArray Bioscience Corporation, Frederick, MD) in conjunction with the TrueLabeling-AMP linear RNA amplification kit, according to manufacturer's protocols. Expression profiles from array experiments were analyzed by using GEArray expression analysis suite (SuperArray Bioscience Corporation).
IP assays
One hundred million cells were used as starting material and lysate supernatants were precleared for 30 min at 4 1C using 15 mg of immunoglobulin G (IgG) (Santa Cruz Biotechnology) and 50 ml of protein A-Sepharose beads (Sigma-Aldrich, St Louis, MO) that had been previously swollen in NT2 buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1 mM MgCl 2 and 0.05% Nonidet P-40 [NP-40]) supplemented with 5% bovine serum albumin. Beads (100 ml) were incubated (16 h, 4 1C) with 30 mg of antibody (either goat IgG (Santa Cruz Biotechnology) or with rabbit anti-menin (BL342) polyclonal antibody (Bethyl)) and then for 1 h at 4 1C with 3 mg of cell lysate. After extensive washes and digestion, proteins were extracted from the beads using Laemmli buffer and detected by western blot analysis.
Gel-retardation and UV-crosslinking assays Gel-retardation reactions were carried out using 500 ng of purified menin protein (gift from Professor M Timmers) or 20 mg of cellular extracts and 5 ng of 32 P-labeled pT7MEN1 RNA or 5 ng of pT7-MEN1-3 0 UTR (heated to 70 1C and allowed to cool and refold slowly) in binding buffer (30 mM Tris/HCl, pH 7.6, 5 mM MgCl 2 , 40 mM NaCl, 2 mM dithiothreitol and EDTA-free protease inhibitor cocktail) in a total volume of 20 ml at 25 1C for 30 min. For competition experiments, labeled and unlabeled RNA were added simultaneously. Complexes were separated on 5% (w/v) nondenaturing polyacrylamide gels (79:1, 0.5 Â TBE (1 Â TBE ¼ 45 mM Tris/borate/1 mM EDTA) at 20 V cm -1 for 3 h at 4 1C). Gels were dried and analyzed bya Cyclone Phosphoimager (Perkin-Elmer).
For the UV crosslinking experiments, 5 ng of 32 P-labeled pT7MEN1 RNA was incubated with 500 ng of purified menin protein that had been preincubated with unlabeled specific, or nonspecific, competitor RNA. The binding reaction products were placed on ice and exposed to UV light for 40 min using a 254 nm 25 W germicidal lamp placed 3 cm above the samples. Following the exposure, the samples were treated for 30 min with RNase A (1 mg ml -1 ) and RNase T1 (2.5 units ml -1 ). Samples were then boiled for 5 min in 5 Â Laemmli buffer and run 20  270  740  738del4  22  260  840 RNA silencing therapy in MEN1 gene mutation carriers E Luzi et al on 12-15% SDS/polyacrylamide gel. The gels were dried and subject to Cyclone Phosphoimager to visualize the proteins tagged because of the label transfer.
Statistical analysis
Statistical analyses were performed by using the paired Student's t-test. A P-value o0.05 was considered statistically significant.
Results
MEN1 mRNA and menin expression in fibroblast primary cells
The expressions of MEN1 mRNA and menin protein were evaluated in skin fibroblasts derived both from MEN1 patients, with two different MEN1 heterozygotetruncating mutations, and from healthy controls. MEN1 patients, A and B, were two sisters, exhibiting a frame-RNA silencing therapy in MEN1 gene mutation carriers E Luzi et al shift, 738del4 (exon 3), MEN1 germline mutation introducing a premature stop codon. MEN1 patient C exhibited a nonsense point germline mutation, R460X (exon 10). Northern expression analysis of MEN1 mRNA in normal skin fibroblasts (H A49) and in fibroblasts from patient A (MEN1-A), from patient B (MEN1-B) and from patient C (MEN1-C) showed that the ubiquitously expressed 2.9-kb transcript was expressed with a difference between wild-type MEN1 mRNA expression in control H fibroblasts versus fibroblasts obtained from MEN1 patients A, B and C, being more expressed in control healthy homozygote fibroblasts (Figure 1a) . A larger transcript (4.2 kb) was expressed only in control H fibroblasts. Relative real-time qRT-PCR analysis confirmed a different expression level between healthy controls and MEN1 patients (Figure 1b) , with mRNA levels in the three patients being about 50% lower than in the controls, suggesting that, in the heterozygote status, wild-type mRNA transcription is not affected, whereas the mutant transcripts were unstable and degraded.
A cellular surveillance mechanism, which could account for our observation, is NMD. Transcripts harboring a premature translation termination (nonsense) codon are known to be detected at the ribosome during the first round of translation, followed by elimination through the NMD pathway. 31 To investigate whether MEN1 mutant transcripts in the three patients were generated, but undergone degradation by NMD, we treated cultured cells of these individuals with the translation inhibitor puromycin. As NMD is a translation-dependent process, the drug can be used to increase the abundance of transcripts that otherwise would be degraded. 31 Exposure of three nonsense mutation cultured cells to puromycin resulted in statistically significant increase of MEN1 mutant transcripts levels by about 7-8-fold compared with the wild-type healthy cultured cells, which serve as negative control (Figure 1c ). In the three nonsense mutation cultured cells, a similar augmentation of MEN1 mutant transcripts was measured both after 6 and 12 h of puromycin treatment. The expression of the full-length menin protein by western blot analysis did not evidence any difference between the healthy controls and the MEN1 fibroblasts (Figure 1d ). To confirm these data and to evaluate the sensitivity of western blot to detect small protein variation, the experiments were repeated three times and menin expression was quantified (Figure 1e ). The absolute expression of menin did not differ between two healthy controls and MEN1 patients. No truncated peptides were detected by using specific antibodies against the truncated forms of the protein (the frameshift 738del4 (exon 3) mutation introducing a premature stop codon and the individual with an R460X (exon 10) nonsense mutation, data not shown).
We hypothesized that these data indicated a compensatory induction of the wild-type allele because of the inactivation of the mutant allele. Thus, mutant MEN1 mRNA may post-transcriptionally regulate the expression of the wild-type menin oncosuppressor mRNA in MEN1 patients. To exclude any transcriptional interference, we performed 11q13 LOH analysis in fibroblasts versus blood DNA samples from MEN1 patients, showing no allelic loss. We also examined the relative levels of both MEN1 mRNA and menin expression in MEN1 (Tables 1a and 1b) . Western blot analysis of lysates from MEN1 tissues did not show any expression of menin protein, as expected for MEN1 tissues with LOH ( Figure 1f) . Menin was expressed only in a lysate from healthy parathyroid tissue. These data were confirmed by MEN1 mRNA profile expression of these tissues by qRT-PCR. MEN1 adenomas showed no expression of MEN1 mRNA compared with the healthy control (Figure 1g ). Both expression profiles of MEN1 mRNA and menin were independent of the kind of mutation (Table 1b) .
Down-regulation of MEN1 mRNA and feedback expression of menin protein
Menin expression was analyzed after siRNA-mediated down-regulation of MEN1 mRNA in both wild-type (healthy) and mutant (patients) status. Very effective siRNA, against MEN1 mRNA region, shared by both wild-type and mutant mRNAs, or against nuclear lamin (as a positive control) were transfected into normal and MEN1-A skin primary fibroblast cultures. Comparative quantitative mRNA analysis of the transfected cells indicated that a statistically significant 80% siRNAinduced reduction of MEN1 mRNA expression was paralleled by a decrease of menin protein levels, as shown by immunoblot analysis of transfected cells lysates, in both wild-type (healthy) and mutant (patient A) cells (Figures 2a and b) .
To exclude the possibility that the transfection reagent or process causes cytotoxicity or other nonspecific effects, the efficiency and specificity of the MEN1 mRNA downregulation was confirmed by transfection with negative nontargeted siRNA control (siRNA against the bacterial lacZ mRNA) and mock-transfected cells. Both comparative real-time qRT-PCR analysis (Figure 2a ) and western blot analysis (Figure 2b ) indicated that there was no reduction of both MEN1 mRNA and menin protein, thus confirming the specificity of MEN1 mRNA siRNA downregulation (Figures 2a and b) . Transfection in primary fibroblast cultures from patient B (MEN1-B) and from patient C (MEN1-C) confirmed these results (data not shown). Thus, the mechanism of compensation required the integrity of the wild-type MEN1 allele.
In order to confirm this hypothesis, two specific 'hammerhead' ribozymes were engineered to downregulate specifically the wild-type or the mutated allele. These ribozymes discriminated between the wild-type GUC triplet and the GUC triplet generated by the frameshift 738del4 (exon 3) of patient A. It was not possible to design a specific ribozyme for the nonsense germline mutation R460X (exon 10) capable to discriminate between the two different alleles. Comparative realtime qRT-PCR mRNA analysis of the transfected cells Menin compensation affects downstream target pro-caspase 8 expression As menin interacts with different molecular partners, we analyzed the effect of menin compensation on a specific cancer expression pathway. Through GEArray Q series human cancer pathway finder Gene Array (HS-006), we studied the expression profile in patients A and B cells transfected with both wild-type ribozyme and ribozyme 738del4. Caspase 8 resulted to be the only gene regulated by menin in this cancer pathway, confirming that menin worked as a transcription factor as well. Enhanced expression of menin protein induced by the silencing of the MEN1 mutant allele caused a significant increase of pro-caspase 8 mRNA levels, as assessed by comparative real-time qRT-PCR in cells from patient A (Figure 4a) . Conversely, in the same cellular model, the down-regulation of wild-type MEN1 allele failed to induce pro-caspase 8 mRNA expression (Figure 4a) . The enhanced expression of pro-caspase 8 mRNA induced the expression of pro-caspase 8 protein in menin-compensated cells compared with MEN1 fibroblasts transfected with the wild-type ribozyme and the inactive molecules (Figure 4b , inverted, inactive and wild-type forms).
In vitro RNA-protein complex formation We speculated that this discrepancy might be accounted for RNA processing and translational events that occur post-trascriptionally. Post-transcriptional regulation of gene expression is a ribonucleoprotein-driven process. The possibility that menin could have an RNA-binding activity on its mRNA was evaluated by gel-retardation assay. Purified menin protein (gift from Professor M Timmers) was incubated with 32 P-labeled full-length MEN1 mRNA. The majority of the input RNA formed a distinct complex whose electrophoretic migration was retarded in the gel (Figure 5a, lane 2) . Binding of the proteins was investigated by carrying out competition experiments. The addition of a 100-fold molar excess of unlabeled full-length MEN1 mRNA transcript completely abolished the slowly migrating complex, and the 32 Plabeled RNA migrated nearly as rapidly as the naked RNA (Figure 5a, lane 3 versus 2) . The occurrence of the slowly migrating complex was not prevented by competition with either a similar-sized RNA transcript of pGEM vector sequences or with other unrelated RNA sequences (data not shown). UV-crosslinking was used to validate this data. As shown in Figure 5c (Figure 5b , lane 5), whereas no effect was observed using a similar-sized RNA transcript of pGEM vector sequences (Figure 5b, lane 4) .
Immunoprecipitaqtion of RNA-proteins complexes from the MEN1-A patient extracts confirmed the presence of menin protein in the complex (Figure 5c ).
Discussion
Little is known about how the MEN1 gene expression, its mRNA transcription and menin translation themselves are regulated. In this study, the expression of both MEN1 mRNA and menin protein was analyzed in skin primary fibroblast cultures from MEN1 patients harboring two different MEN1 gene-truncating mutations and in healthy skin primary fibroblasts.
Although both alleles, the mutant and the wild type, are expressed at different levels, as shown by both northern blot and real-time qRT-PCR analysis, no truncated protein was found in extracts from skin fibroblasts from MEN1 patients harboring two different MEN1 genetruncating mutations, suggesting a fast degradation of the nonfunctional protein. It has been reported that missense mutants were rapidly degraded through the ubiquitinproteasome pathway, 33 but there was not the same evidence for nonsense and frameshift mutations.
Interestingly, it appears that regulatory mechanisms maintain a constant level of wild-type menin expression, independently on whether both alleles are functional. Therefore, a compensatory regulatory mechanism could enable the maintenance of a physiological level of menin expression even in mutated cells, indicating an attempt to compensate for allelic mutation by up-regulating the expression of wild-type menin. The mechanism of MEN1 gene compensation seemed to require the integrity of the wild-type MEN1 mRNA, as shown by siRNA-mediated down-regulation of wild-type mRNA in primary fibroblasts both from healthy controls and from MEN1 patients. In addition, parathyroid adenomas from MEN1 patients with four different MEN1 mutations were analyzed for both MEN1 mRNA and menin expression and compared with normal parathyroid tissue. The loss of MEN1 mRNA and menin expression resulted not dependent on the kind of mutation, but on the LOH at chromosome 11q13.
Interestingly, selective and specific down-regulation of the mutant allele in MEN1 fibroblasts, through 'hammerhead' ribozymes, made possible to show that inactivation of the mutant allele was the signal for the strongly enhanced menin-oncosuppressor expression induction. This finding was confirmed by the inactivation of the wild-type mRNA, as the menin compensation was lost even if the mutant mRNA was expressed. In the presence of reduced menin, a strong compensatory activity was induced, supporting the hypothesis that the reduced expression of a tumor-suppressor gene is not tolerated by the system. Such a transcriptional feedback was previously suggested to occur in lymphoblastoid cell lines from two MEN1 patients, even if an analysis of MEN1 mRNA expression was never performed. 24 Moreover, in an inducible cell culture system, an over-expression of menin has been reported to down-regulate the MEN1 proximal promoter, whereas the silencing of MEN1 mRNA expression activated the promoter in a compensatory manner. 29 Although the EcR-293 cell lines (human embryo kidney 293) used did not derive from tissues that are not usually affected by the MEN1 syndrome and, mainly, any increase of the endogenous MEN1 mRNA was never shown, the authors proposed a transcriptional feedback exerted by menin on MEN1 gene expression. 24, 29 In this study, the simultaneous analysis of both MEN1 mRNA and menin expression in MEN1 primary fibroblast cultures made possible to propose a mechanism of compensation for allelic mutation by up-regulating the expression of menin active at a post-transcriptional level, as menin compensation did not require an increase of MEN1 mRNA transcription. In fact, for the enhancement of menin-oncosuppressor expression, the integrity of wildtype MEN1 mRNA, but not its transcriptional increase, is needed. The NMD pathway seems to trigger degradation of MEN1 mRNA alleles bearing premature termination codons. As truncating mutations were associated with reduced transcript amounts while transcripts synthesized from alleles maintaining the reading frame were expressed at a steady-state level, this could represent the mechanisms for the induction of menin compensation. 34 The fact that the steady-state levels of mRNA in a cell do not always directly correlate with the steady-state protein levels may be explained on the basis of the RNA processing and translational events that occur post-transcriptionally through a ribonucleoprotein-driven process.
For the first time, we showed that menin was able to bind to its mRNA and that a specific RNA-protein complex was present in fibroblast cells from MEN1 patients, offering an explanation for the menin compensatory phenomenon, as an autoregolatory loop driven by an RNA-protein-mediated mechanism. Interestingly, the development of tumors in the typical endocrine-specific pattern is puzzling, as menin appears to be expressed in all tissues. Indeed, most hereditary predisposition to tumors affects only some particular cell types in the body, but the genes carrying the relevant germline mutation are not celltype specific. Candidate cell-type-specific regulators may be microRNAs. 35 As RNA expression analyses have identified several menin-regulated genes that could represent proximal or distal interaction sites for menin, 21 the present demonstration of menin binding to RNA opens the possibility that these proximal and distal interactions could be RNA-protein driven. A ribonucleoprotein structure in which multiple mRNAs were coordinately regulated by RNA-binding proteins and small noncoding RNAs (RNA regulons) 36 could be involved and this could be cell and time specific.
Finally, we showed that menin compensation affects the expression of the downstream target pro-caspase 8. These data suggested that menin could suppress tumorigenesis by promoting apoptosis. The fact that RNA silencing of the mutant allele induced the compensation of menin oncosuppressor and pro-caspase 8 expression opens the possibility for a RNA-based therapy in MEN1 gene mutation carriers through the increase of the oncosuppressor protein and the induction of apoptosis.
In conclusion, the present findings offer a novel interpretation of menin compensation for allelic loss through the up-regulation of the menin-oncosuppressor expression at a post-transcriptional level, through the interaction of menin protein with MEN1 mRNA and/or the formation of a specific ribonucleoprotein complex, where RNA-binding proteins and small noncoding RNAs could work in a coordinated pattern. The possibility of using in vitro RNA silencing for the correction of MEN1 gene mutation consequences opens new avenues for future developments of RNA-based strategies in the in vivo control of tumorigenesis in MEN1.
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